Our Company

biOasis Technologies Inc. (TSX-V:BTI) is a publically traded biopharmaceutical company focused on developing and commercializing proprietary pharmaceutical products and diagnostic technologies for central nervous system ("CNS") diseases and disorders. Of particular interest is the creation of therapeutic options for patient management to address the limitations to biodistribution presented by the properties of the blood-brain barrier ("BBB"). 



Our Business Strategy
BTI's business strategy emphasizes out-licensing its technologies to qualified partners, and strategic acquisitions of products and technologies relevant to the diagnosis and management of CNS diseases and disorders.

For more about our current development programs click here...
 

transcend

TRANSCEND is a protein Vector that shuttles existing therapeutic drugs across the Blood-Brain Barrier. In November 2010 Bioasis sponsored a research agreement with the National Research Council of Canada to evaluate the ability of biOasis' compounds to cross the blood-brain barrier using real time-domain in vivo optical imaging.
More
 

Media & Research

September 9, 2014
biOasis Advances Its Lysosomal Storage Disease Program with a Knockout Model for Sandhoff Disease
BIOASIS TECHNOLOGIES INC. (OTCQX:BIOAF; TSXV:BTI), announces the commencement of a new phase of its Lysosomal Storage Disease program with a study focused on a knockout model for Sandhoff Disease. The study, to be conducted at The University of British Columbia ("UBC"), will assess the use of therapeutics based on biOasis' proprietary Blood-Brain Barrier vectors, Transcend and Transcendpep, to correct enzyme deficiencies within the Central Nervous Systems of genetically engineered animals deficient in the enzyme β-hexosaminidase subunit beta ("HEXB"), which is functionally deficient in sufferers of Sandhoff Disease.
More
 

News

Loading...